EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE )

Worel Nina iD, Schreder Martin iD, Tanzmann Andreas, Kurz Martin iD, Huber-Kraßnitzer Bianca, Neumeister Peter, Rosskopf Konrad, Sareban Nazanin, Branka Manuela, Kolovratova Vera, Oesterreicher Sophia, Koerbler Beatrix und 6 weitere

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70188 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Apheresis, 2026. Verfasst von Worel Nina und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Multiple Myeloma, Cyclams, Benzylamines, Hematopoietic Stem Cell Mobilization. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Genzyme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient collection of hematopoietic progenitor cells (HPCs) is essential for autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Although plerixafor is routinely used in poor mobilizers, its role in patients with intermediate mobilization capacity remains unclear. In this randomized, double‐blind, placebo‐controlled phase IV trial, MM patients with peripheral blood (PB) CD34 + counts of 15–40 cells/μL after steady‐state G‐CSF mobilization were randomized to receive plerixafor or placebo. The primary endpoint was successful collection of ≥ 6.0 × 10 6 CD34 + cells/kg, sufficient for two ASCTs, during a single apheresis session. Secondary endpoints included CD34 + kinetics, graft composition, colony‐forming capacity, engraftment, immune reconstitution, and safety. Twenty‐one patients were enrolled before premature study termination due to changes in first‐line MM therapy and the COVID‐19 pandemic. Plerixafor significantly increased PB CD34 + cell counts compared with placebo ( p < 0.001). All patients receiving plerixafor achieved the primary endpoint, whereas none in the placebo group achieved it ( p < 0.001). Mean CD34 + yield was significantly higher with plerixafor (10.4 ± 1.9 × 10 6 /kg vs. 2.9 ± 1.3 × 10 6 /kg; p < 0.001). Plerixafor‐mobilized grafts contained significantly higher numbers of primitive hematopoietic progenitor subsets and demonstrated increased CFU‐GM formation, indicating enhanced clonogenic potential. Despite marked differences in graft quantity and quality, engraftment kinetics, graft sustainability, and immune reconstitution were comparable between groups. In MM patients with intermediate mobilization capacity, the addition of plerixafor markedly improved stem cell mobilization efficiency and enriched grafts with functionally robust progenitor cells. These findings suggest that selected patients beyond conventional poor mobilizers may benefit from plerixafor‐assisted mobilization. Trial Registration: EudraCT nr.: 2016‐004122‐41

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaCyclamsBenzylaminesHematopoietic Stem Cell MobilizationGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedAntigens, CD34Hematopoietic Stem Cell TransplantationTransplantation, AutologousAdultHematopoietic Stem Cells

Stichwörter der Autor:innen

autologous stem cell transplantationcolony‐forming unitshematopoietic stem cell mobilizationmultiple myelomaplerixaforstem cell graft composition

Substanzen

plerixaforCyclamsBenzylaminesGranulocyte Colony-Stimulating FactorAntigens, CD34Heterocyclic Compounds

Autor:innen und Institutionen

  • Department of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
  • Department of Internal Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria.
  • Division of Hematology, Medical University of Graz, Graz, Austria.
  • Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine II, Clinic Donaustadt, Vienna, Austria.
  • Department of Internal Medicine 1, BMT-Unit, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Worel Nina, Schreder Martin, Kurz Martin, Agis Hermine

Förderung

  • Sanofi Genzyme

Zitieren

APA

Nina, W., Martin, S., Andreas, T., Martin, K., Bianca, H. K., Peter, N., Konrad, R., Nazanin, S., Manuela, B., Vera, K., Sophia, O., Beatrix, K., Elvira, K., Reinhard, R., Werner, R., Hermine, A., Maria, K., & T, G. H. (2026). Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE ). Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70188

Vancouver

Nina W, Martin S, Andreas T, Martin K, Bianca HK, Peter N, et al. Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE ). Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70188

BibTeX
@article{Nina2026,
  author = {Nina, Worel and Martin, Schreder and Andreas, Tanzmann and Martin, Kurz and Bianca, Huber-Kraßnitzer and Peter, Neumeister and Konrad, Rosskopf and Nazanin, Sareban and Manuela, Branka and Vera, Kolovratova and Sophia, Oesterreicher and Beatrix, Koerbler and Elvira, Kitzweger and Reinhard, Ruckser and Werner, Rabitsch and Hermine, Agis and Maria, Krauth and T, Greinix Hildegard},
  title = {Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE )},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70188}
}
Kostenlos starten →